ClinicalTrials.gg
Active, not recruitingNCT05011123Updated Jun 1, 2026Results posted

Study on an Investigational Yellow Fever Vaccine Compared With Stamaril in Adults in Europe and Asia

A Phase 2 interventional study of Yellow fever vaccine (produced on serum-free Vero cells) and Yellow fever vaccine in Yellow Fever, sponsored by Sanofi Pasteur, a Sanofi Company. Active, not recruiting at 23 sites in 6 countries. Open to participants aged 18 Years to 59 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
690
Allocation
Randomized
Ages
18 Years to 59 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing Yellow Fever Vaccine in Yellow Fever — 3 open to participants now, 7 under way, 1 of them phase 3. Yellow Fever Vaccine · Yellow Fever.

Enrollment
4th of 18
690 · median 181
Started
2021
with 2 others
Phase 2
4 of 18
none open now
Registered
12th of 18
by date
Lead sponsor
4 of 18
Sanofi Pasteur, a Sanofi Company

Among the 18 studies testing Yellow Fever Vaccine in Yellow Fever, this one is the 4th largest by enrollment, is one of 3 that started in 2021, is one of 4 in phase 2, and was the 12th registered.

Yellow Fever

52 studies on the registry are indexed under Yellow Fever; 10 are open to participants now.

Browse Yellow Fever studies →

Open to participants now

3 of the 18 studies testing Yellow Fever Vaccine in Yellow Fever are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Yellow Fever Vaccine

Yellow Fever Vaccine: first FDA approval 1999 (Yf-Vax). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 7 Yellow Fever studies recruiting now, 1 sets no upper age limit and 6 stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 59 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing Yellow Fever Vaccine in Yellow Fever, or all of them as a file.
02

Study summary

VYF03 is a phase II, randomized, parallel-group prevention study with 2 arms, active-controlled (Stamaril), observer-blind, multi-center study to assess the non-inferiority of the immune response, in terms of seroconversion rates of the investigational vaccine candidate vYF to the licensed Stamaril, in adults aged 18 years up to 60 years in Europe (EU).

The safety and immunogenicity profile of vYF in a cohort of Asian population of Chinese origin outside of China will also be described. The study will also assess the immunogenicity profiles and the safety profiles of vYF and Stamaril.

Participants will be randomized in a 2:1 ratio to receive a single subcutaneous injection of either the vYF vaccine (380 participants in EU and 80 participants of Chinese origin in Asia) or Stamaril (190 participants in EU and 40 participants of Chinese origin in Asia), on Day 01.

The duration of each participant's participation will be approximately 5 years.

Read the detailed description

The duration of each participant's participation will be approximately 5 years.

03

Conditions studied

  • Yellow Fever

Browse trials for

04

Who can participate

Ages eligible
18 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 years up to 60 years* on the day of inclusion
  • A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies:

Is of non-. To be considered of non-childbearing potential, a female must be for at least 1 year, or surgically sterile OR Is of childbearing potential and agrees to use an effective method (1) or abstinence (1) from at least 4 weeks prior to study intervention administration until at least 4 weeks (2) after study intervention administration.

*18 to 60 years means from the day of the 18th birthday up to the day before the 60th birthday

  1. Not applicable for Finland
  2. Except for French participants which have to apply 12 weeks contraception after study intervention administration A female participant of childbearing potential must have a negative highly sensitive pregnancy test (urine or serum as required by local regulation) before any dose of study intervention on Day 1 and the test will be repeated on D29 to confirm the participant is still not pregnant within 28 days of vaccine administration.

    - form has been signed and dated (3)

  3. For participants aged less than 21 years in Singapore, an informed consent form has been signed and dated by both the participant and the parent(s) or another legally acceptable representative

    • Able to attend all scheduled visits and to comply with all study procedures
    • For participants enrolled in Asian countries as part of the additional cohort only: know Chinese origin, defined as having at least one biological parent of Chinese origin, and will be self-reported by the participant

Exclusion criteria

Exclusion Criteria:

Participation at the time of study enrollment (or in the 4 weeks preceding the study vaccination) or planned participation during the first 2 years of the 5-year follow-up in another clinical study investigating a vaccine, drug, medical device, or medical procedure. Enrollment in another study after the first 2 years is permitted, assuming that it does not exclude participation in this study.

  • Receipt of any vaccine in the 4 weeks preceding the study vaccination or planned receipt of any vaccine in the 4 weeks following the study vaccination (prior to visit 4), except for influenza vaccination, which may be received at least 2 weeks before study vaccines (4). This exception includes all influenza vaccines including monovalent pandemic influenza vaccines.
  • Previous vaccination against a FV disease at any time including YF with either the study vaccine or another vaccine.
  • Receipt of immune globulins, blood, or blood-derived products in the past 6 months.
  • Known or suspected congenital or acquired immunodeficiency; or receipt of therapy, such as anti-cancer chemotherapy, or radiation therapy, within the preceding 6 months; or long-term systemic therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).
  • Known history of any FV infection.
  • Known systemic to any of the vaccine components, eggs, or history of a life-threatening reaction to the vaccines used in the study or to a vaccine containing any of the same substances.
  • Known history or laboratory evidence of infection (5).
  • Known history or laboratory evidence of or infection (6).
  • Personal or family history of thymic pathology (thymoma, thymectomy, or myasthenia).
  • Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily.
  • Alcohol, prescription drug, or substance abuse that, in the opinion of the Investigator, might interfere with the study conduct or completion.
  • Chronic illness (7) that, in the opinion of the Investigator, is at a stage where it might interfere with trial conduct or completion, including , such as leukemia, or lymphoma.
  • Moderate or severe acute illness/infection (according to Investigator judgment) on the day of vaccination or febrile illness (temperature ≥ 100.4°F or 38°C). A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided.
  • Administration of any anti-viral within 2 months preceding the vaccination and planned administration up to the 6 weeks following the vaccination.
  • Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (ie, parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study.
  • Planned travel in a YF endemic country within 6 months of or control vaccine administration.
  1. Except for Thai participants
  2. HIV Serology testing will be performed on all German participants if no evidence of seronegativity in the 90 days preceding vaccination
  3. Hepatitis B and Hepatitis C Serology testing will be performed on all German participants if no evidence of seronegativity in the 90 days preceding vaccination
  4. Chronic illness may include, but is not limited to, cardiac disorders, renal disorders, auto-immune disorders, diabetes, psychiatric disorders or chronic infection
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
690 participants (actual)

Study arms

  • Experimental
    Group 1

    1 injection of vYF vaccine at Day 1

    Biological: Yellow fever vaccine (produced on serum-free Vero cells)

  • Active comparator
    Group 2

    1 injection of Stamaril vaccine at Day 1

    Biological: Yellow fever vaccine

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Yellow Fever-naive Participants Who Achieved Seroconversion 28 Days Post Dose 1 Enrolled in European Union

    Seroconversion was defined as a 4-fold increase in Nab titers as compared to the pre-vaccination value. YF-naive participants (or negative) at baseline corresponded to participants with no detectable YF Ab titers before vaccination. The YF NAb titers were determined using a validated live virus microneutralization (MN) assay. Percentages are rounded off to the tenth decimal place.

    Time frame: 28 days post dose 1 (Day 29)

Secondary outcomes

  1. Percentage of Participants Who Achieved Seroconversion 28 Days Post Dose 1 Enrolled in European Union

    Seroconversion was defined as a 4-fold increase in Nab titers as compared to the pre-vaccination value. The YF NAb titers were determined using a validated live virus MN assay. Percentages are rounded off to the tenth decimal place.

    Time frame: 28 days post dose 1 (Day 29)

  2. Percentage of Participants Who Achieved Seroconversion Enrolled in European Union and Asia

    Seroconversion was defined as a 4-fold increase in Nab titers as compared to the pre-vaccination value: as compared to the Day 1 titers at each timepoint up to Month 6; as compared to the last planned previous timepoint from Year 1 onwards. The YF NAb titers were determined using a validated live virus MN assay. Percentages are rounded off to the tenth decimal place.

    Time frame: Days 1, 11, 29, Month 6, Years 1 and 2

  3. Percentage of Participants Who Achieved Seroprotection to Yellow Fever Virus Enrolled in European Union and Asia

    Seroprotection was defined as NAb titers \>=threshold of 10 (1/dilution). YF-naive participants (or negative) at baseline corresponded to participants with no detectable YF Ab titers before vaccination. The YF NAb titers were determined using a validated live virus MN assay. Percentages are rounded off to the tenth decimal place.

    Time frame: Days 1, 11, 29, Month 6, Years 1 and 2

  4. Geometric Mean Titers (GMTs) of Antibodies Against Yellow Fever Virus in Participants Enrolled in European Union and Asia

    GMTs of antibody against YF virus was measured using a validated live virus MN assay.

    Time frame: Days 1, 11, 29, Month 6, Years 1 and 2

  5. Geometric Mean Titers Ratio (GMTRs) of Antibodies Against Yellow Fever Virus in Participants Enrolled in European Union and Asia

    GMTs of antibody against YF virus was measured using a validated live virus MN assay. Ratio was calculated as post-vaccination titer at Days 11, 29 and Month 6 to pre-vaccination titer at Day 1; post-vaccination titer at Year 1 to pre-vaccination titer at Month 6; post-vaccination titer at Year 2 to pre-vaccination titer at Year 1.

    Time frame: Days 1, 11, 29, Month 6, Years 1 and 2

  6. Number of Participants With Unsolicited Systemic Adverse Events (AEs)

    An unsolicited AE was an observed AE that did not fulfill the conditions of solicited reactions, ie, pre-listed in the CRF in terms of diagnosis and onset window post-vaccination.

    Time frame: Up to 30 minutes post vaccination on Day 1

  7. Number of Participants With Solicited Injection Site Reactions

    A solicited reaction was an "expected" adverse reaction (AR) (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRF. An injection site reaction was an AR at and around the injection site of the study vaccine.

    Time frame: Up to 7 days post vaccination (Day 8)

  8. Number of Participants With Solicited Systemic Reactions

    A solicited reaction was an "expected" AR (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRF. Solicited systemic reactions were systemic AEs observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRF.

    Time frame: Up to 14 days post vaccination (Day 15)

  9. Number of Participants With Unsolicited Adverse Events

    An unsolicited AE was an observed AE that did not fulfill the conditions of solicited reactions, ie, pre-listed in the CRF in terms of diagnosis and onset window post-vaccination.

    Time frame: Up to 28 days post vaccination (Day 29)

  10. Number of Participants With Any Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs) up to 6 Months Post-Vaccination

    An SAE was any AE that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. An AESI (serious or non-serious) was defined as one of scientific and medical concern specific to the Sponsor's study intervention or program, for which ongoing monitoring and rapid communication by the Investigator to the Sponsor could be appropriate. AESIs included serious hypersensitivity/allergic reactions, organ failure/serious viscerotropic events, serious neurologic events.

    Time frame: From the first dose of study vaccine administration (Day 1) up to 6 months post vaccination, approximately up to Day 181

  11. Number of Participants With Serious Adverse Events and Deaths up to Day 1030

    An SAE was any AE that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event.

    Time frame: From the first dose of study vaccine administration (Day 1) up to DBL date of 01 August 2024, approximately up to Day 1030

  12. Number of Participants With Serious Adverse Events and Deaths Up to Year 5

    An SAE was any AE that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event.

    Time frame: From the first dose of study vaccine administration (Day 1) up to end of study, approximately 5 years

07

Results

Posted May 21, 2025

Participant flow

This study was conducted at 23 sites in 6 countries in Europe and Asia from 07 October 2021 to 25 April 2022. Interim results are presented up to Year 2 follow-up, data base lock (DBL) date of 01 August 2024.

Participant flow — Overall Study
MilestonevYF 0.5 mLStamaril 0.5 mL
Started455235
Randomized and vaccinated454235
Completed407217
Not completed4818
Withdrew: Withdrawal by subject42
Withdrew: Lost to follow-up76
Withdrew: Ongoing at the time of dbl date3610
Withdrew: Randomized but did not receive vaccination10

Outcome measures

PrimaryPercentage of Yellow Fever-naive Participants Who Achieved Seroconversion 28 Days Post Dose 1 Enrolled in European Union

Seroconversion was defined as a 4-fold increase in Nab titers as compared to the pre-vaccination value. YF-naive participants (or negative) at baseline corresponded to participants with no detectable YF Ab titers before vaccination. The YF NAb titers were determined using a validated live virus microneutralization (MN) assay. Percentages are rounded off to the tenth decimal place.

Time frame:
28 days post dose 1 (Day 29)
Reported as:
Number · percentage of participants
Percentage of Yellow Fever-naive Participants Who Achieved Seroconversion 28 Days Post Dose 1 Enrolled in European Union
percentage of participantsvYF 0.5 mLStamaril 0.5 mL
Percentage of Yellow Fever-naive Participants Who Achieved Seroconversion 28 Days Post Dose 1 Enrolled in European Union98.1 (96.0 to 99.3)99.4 (96.6 to 100)
Statistical analysis
  • vYF 0.5 mL vs Stamaril 0.5 mL · Difference in percentage of participants: -1.2 · 95% CI -3.4 to 1.895% CI of the difference was calculated from the Wilson score method without continuity correction.
SecondaryPercentage of Participants Who Achieved Seroconversion 28 Days Post Dose 1 Enrolled in European Union

Seroconversion was defined as a 4-fold increase in Nab titers as compared to the pre-vaccination value. The YF NAb titers were determined using a validated live virus MN assay. Percentages are rounded off to the tenth decimal place.

Time frame:
28 days post dose 1 (Day 29)
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Seroconversion 28 Days Post Dose 1 Enrolled in European Union
percentage of participantsvYF 0.5 mLStamaril 0.5 mL
Percentage of Participants Who Achieved Seroconversion 28 Days Post Dose 1 Enrolled in European Union95.9 (93.4 to 97.7)96.8 (93.3 to 98.8)
Statistical analysis
  • vYF 0.5 mL vs Stamaril 0.5 mL · Difference in percentage of participants: -0.9 · 95% CI -4.0 to 3.095% CI of the difference was calculated from the Wilson score method without continuity correction.
SecondaryPercentage of Participants Who Achieved Seroconversion Enrolled in European Union and Asia

Seroconversion was defined as a 4-fold increase in Nab titers as compared to the pre-vaccination value: as compared to the Day 1 titers at each timepoint up to Month 6; as compared to the last planned previous timepoint from Year 1 onwards. The YF NAb titers were determined using a validated live virus MN assay. Percentages are rounded off to the tenth decimal place.

Time frame:
Days 1, 11, 29, Month 6, Years 1 and 2
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Seroconversion Enrolled in European Union and Asia
percentage of participantsvYF 0.5 mLStamaril 0.5 mL
EU: Day 1130.4 (18.8 to 44.1)63.6 (45.1 to 79.6)
EU: Day 2995.9 (93.4 to 97.7)96.8 (93.3 to 98.8)
EU: Month 695.8 (93.2 to 97.6)95.2 (91.1 to 97.8)
EU: Year 13.2 (1.6 to 5.7)4.4 (1.9 to 8.4)
EU: Year 20.9 (0.2 to 2.7)3.0 (1.0 to 6.8)
Asia: Day 115.1 (0.6 to 17.3)33.3 (14.6 to 57.0)
Asia: Day 2987.2 (77.7 to 93.7)97.6 (87.4 to 99.9)
Asia: Month 685.7 (75.9 to 92.6)100 (91.0 to 100)
Asia: Year 11.3 (0 to 7.1)0 (0 to 9.3)
Asia: Year 21.3 (0 to 7.2)2.5 (0.1 to 13.2)
SecondaryPercentage of Participants Who Achieved Seroprotection to Yellow Fever Virus Enrolled in European Union and Asia

Seroprotection was defined as NAb titers \>=threshold of 10 (1/dilution). YF-naive participants (or negative) at baseline corresponded to participants with no detectable YF Ab titers before vaccination. The YF NAb titers were determined using a validated live virus MN assay. Percentages are rounded off to the tenth decimal place.

Time frame:
Days 1, 11, 29, Month 6, Years 1 and 2
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Seroprotection to Yellow Fever Virus Enrolled in European Union and Asia
percentage of participantsvYF 0.5 mLStamaril 0.5 mL
EU: Day 14.3 (2.5 to 6.9)7.9 (4.5 to 12.7)
EU: Day 1148.2 (34.7 to 62.0)81.8 (64.5 to 93.0)
EU: Day 2998.6 (96.9 to 99.6)99.5 (97.1 to 100)
EU: Month 698.1 (96.0 to 99.2)100 (98.0 to 100)
EU: Year 198.5 (96.6 to 99.5)99.5 (97.0 to 100)
EU: Year 298.5 (96.5 to 99.5)100 (97.9 to 100)
Asia: Day 16.4 (2.1 to 14.3)7.1 (1.5 to 19.5)
Asia: Day 1128.2 (15.0 to 44.9)66.7 (43.0 to 85.4)
Asia: Day 2996.2 (89.2 to 99.2)100 (91.6 to 100)
Asia: Month 696.1 (89.0 to 99.2)100 (91.0 to 100)
Asia: Year 194.8 (87.2 to 98.6)100 (91.2 to 100)
Asia: Year 296.0 (88.8 to 99.2)100 (91.2 to 100)
SecondaryGeometric Mean Titers (GMTs) of Antibodies Against Yellow Fever Virus in Participants Enrolled in European Union and Asia

GMTs of antibody against YF virus was measured using a validated live virus MN assay.

Time frame:
Days 1, 11, 29, Month 6, Years 1 and 2
Reported as:
Geometric mean · titer
Geometric Mean Titers (GMTs) of Antibodies Against Yellow Fever Virus in Participants Enrolled in European Union and Asia
titervYF 0.5 mLStamaril 0.5 mL
EU: Day 15.62 (5.29 to 5.98)6.18 (5.52 to 6.92)
EU: Day 1126.6 (14.4 to 49.2)52.3 (29.8 to 91.5)
EU: Day 292229 (1928 to 2577)1060 (884 to 1270)
EU: Month 6562 (493 to 641)425 (365 to 495)
EU: Year 1454 (391 to 527)420 (353 to 499)
EU: Year 2310 (268 to 359)349 (292 to 416)
Asia: Day 16.16 (5.13 to 7.39)5.63 (4.83 to 6.57)
Asia: Day 1110.3 (6.36 to 16.7)16.6 (10.0 to 27.7)
Asia: Day 291204 (792 to 1831)1167 (843 to 1616)
Asia: Month 6495 (355 to 690)398 (300 to 527)
Asia: Year 1303 (209 to 438)245 (174 to 344)
Asia: Year 2168 (127 to 223)143 (104 to 196)
SecondaryGeometric Mean Titers Ratio (GMTRs) of Antibodies Against Yellow Fever Virus in Participants Enrolled in European Union and Asia

GMTs of antibody against YF virus was measured using a validated live virus MN assay. Ratio was calculated as post-vaccination titer at Days 11, 29 and Month 6 to pre-vaccination titer at Day 1; post-vaccination titer at Year 1 to pre-vaccination titer at Month 6; post-vaccination titer at Year 2 to pre-vaccination titer at Year 1.

Time frame:
Days 1, 11, 29, Month 6, Years 1 and 2
Reported as:
Geometric mean · ratio
Geometric Mean Titers Ratio (GMTRs) of Antibodies Against Yellow Fever Virus in Participants Enrolled in European Union and Asia
ratiovYF 0.5 mLStamaril 0.5 mL
EU: Day 11/Day 13.12 (1.85 to 5.27)4.92 (3.02 to 8.03)
EU: Day 29/Day 1206 (176 to 241)90.9 (74.1 to 111)
EU: Month 6/Day 152.3 (45.5 to 60.0)36.7 (30.7 to 43.9)
EU: Year 1/Month 60.810 (0.738 to 0.889)0.993 (0.884 to 1.11)
EU: Year 2/Year 10.655 (0.597 to 0.718)0.822 (0.716 to 0.944)
Asia: Day 11/Day 11.31 (1.04 to 1.65)2.05 (1.36 to 3.08)
Asia: Day 29/Day 1105 (67.0 to 164)109 (75.9 to 156)
Asia: Month 6/Day 143.1 (30.0 to 61.7)36.9 (27.4 to 49.8)
Asia: Year 1/Month 60.607 (0.497 to 0.741)0.601 (0.474 to 0.762)
Asia: Year 2/Year 10.542 (0.452 to 0.649)0.585 (0.470 to 0.729)
SecondaryNumber of Participants With Unsolicited Systemic Adverse Events (AEs)

An unsolicited AE was an observed AE that did not fulfill the conditions of solicited reactions, ie, pre-listed in the CRF in terms of diagnosis and onset window post-vaccination.

Time frame:
Up to 30 minutes post vaccination on Day 1
Reported as:
Count of participants · Participants
Number of Participants With Unsolicited Systemic Adverse Events (AEs)
ParticipantsvYF 0.5 mLStamaril 0.5 mL
Number of Participants With Unsolicited Systemic Adverse Events (AEs)00
SecondaryNumber of Participants With Solicited Injection Site Reactions

A solicited reaction was an "expected" adverse reaction (AR) (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRF. An injection site reaction was an AR at and around the injection site of the study vaccine.

Time frame:
Up to 7 days post vaccination (Day 8)
Reported as:
Count of participants · Participants
Number of Participants With Solicited Injection Site Reactions
ParticipantsvYF 0.5 mLStamaril 0.5 mL
Number of Participants With Solicited Injection Site Reactions15250
SecondaryNumber of Participants With Solicited Systemic Reactions

A solicited reaction was an "expected" AR (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRF. Solicited systemic reactions were systemic AEs observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRF.

Time frame:
Up to 14 days post vaccination (Day 15)
Reported as:
Count of participants · Participants
Number of Participants With Solicited Systemic Reactions
ParticipantsvYF 0.5 mLStamaril 0.5 mL
Number of Participants With Solicited Systemic Reactions222126
SecondaryNumber of Participants With Unsolicited Adverse Events

An unsolicited AE was an observed AE that did not fulfill the conditions of solicited reactions, ie, pre-listed in the CRF in terms of diagnosis and onset window post-vaccination.

Time frame:
Up to 28 days post vaccination (Day 29)
Reported as:
Count of participants · Participants
Number of Participants With Unsolicited Adverse Events
ParticipantsvYF 0.5 mLStamaril 0.5 mL
Number of Participants With Unsolicited Adverse Events13868
SecondaryNumber of Participants With Any Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs) up to 6 Months Post-Vaccination

An SAE was any AE that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. An AESI (serious or non-serious) was defined as one of scientific and medical concern specific to the Sponsor's study intervention or program, for which ongoing monitoring and rapid communication by the Investigator to the Sponsor could be appropriate. AESIs included serious hypersensitivity/allergic reactions, organ failure/serious viscerotropic events, serious neurologic events.

Time frame:
From the first dose of study vaccine administration (Day 1) up to 6 months post vaccination, approximately up to Day 181
Reported as:
Count of participants · Participants
Number of Participants With Any Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs) up to 6 Months Post-Vaccination
ParticipantsvYF 0.5 mLStamaril 0.5 mL
SAEs68
AESIs01
SecondaryNumber of Participants With Serious Adverse Events and Deaths up to Day 1030

An SAE was any AE that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event.

Time frame:
From the first dose of study vaccine administration (Day 1) up to DBL date of 01 August 2024, approximately up to Day 1030
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events and Deaths up to Day 1030
ParticipantsvYF 0.5 mLStamaril 0.5 mL
SAEs1111
Deaths00
SecondaryNumber of Participants With Serious Adverse Events and Deaths Up to Year 5

An SAE was any AE that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event.

Time frame:
From the first dose of study vaccine administration (Day 1) up to end of study, approximately 5 years

Results for this outcome have not been posted.

Adverse events

Collected over AEs, SAEs and all-cause mortality (deaths) were collected from the first dose of study vaccine administration (Day 1) up to DBL date of 01 August 2024, approximately up to Day 1030.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
vYF 0.5 mL0/454 (0%)11/454 (2.4%)266/454 (58.6%)
Stamaril 0.5 mL0/235 (0%)11/235 (4.7%)141/235 (60%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventvYF 0.5 mLStamaril 0.5 mL
Covid-19Infections and infestations1/4543/235
PyelonephritisInfections and infestations2/4540/235
Acute Myocardial InfarctionCardiac disorders0/4541/235
AppendicitisInfections and infestations0/4541/235
InfluenzaInfections and infestations0/4541/235
TonsillitisInfections and infestations0/4541/235
Femoral Neck FractureInjury, poisoning and procedural complications0/4541/235
Cerebrovascular AccidentNervous system disorders0/4541/235
Transient Ischaemic AttackNervous system disorders0/4541/235
Suicidal IdeationPsychiatric disorders0/4541/235
Most frequent other events
Most frequent other events
EventvYF 0.5 mLStamaril 0.5 mL
HeadacheNervous system disorders168/45499/235
Injection Site PainGeneral disorders144/45449/235
MyalgiaMusculoskeletal and connective tissue disorders123/45465/235
MalaiseGeneral disorders105/45461/235
Injection Site ErythemaGeneral disorders30/4541/235

Baseline characteristics

The randomized population included all participants with data in the case report form (CRF).

Age, Continuous
Age, Continuous(Years)vYF 0.5 mLStamaril 0.5 mLTotal
Mean37.1 ± 11.7637.1 ± 11.5137.1 ± 11.67
Sex: Female, Male
Sex: Female, Male(Participants)vYF 0.5 mLStamaril 0.5 mLTotal
Female253136389
Male20299301
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)vYF 0.5 mLStamaril 0.5 mLTotal
American Indian or Alaska Native112
Asian8543128
Black or African American527
Native Hawaiian or Other Pacific Islander101
White356187543
Multiple origin325
Not Reported202
Unknown202
08

Study locations

23 sites
  • Investigational Site Number : 2460001
    Helsinki, 00290, Finland
  • Investigational Site Number : 2460002
    Tampere, 33100, Finland
  • Investigational Site Number : 2460003
    Turku, 20520, Finland
  • Investigational Site Number : 2500008
    Lyon, 69004, France
  • Investigational Site Number : 2500006
    Montpellier, 34295, France
  • Investigational Site Number : 2500001
    Nantes, 44093, France
  • Investigational Site Number : 2500007
    Nîmes, 30029, France
  • Investigational Site Number : 2500009
    Paris, 75014, France
  • Investigational Site Number : 2500004
    Pierre-Bénite, 69495, France
  • Investigational Site Number : 2760004
    Berlin, 10117, Germany
  • Investigational Site Number : 2760001
    Hamburg, 20359, Germany
  • Investigational Site Number : 2760002
    München, 80802, Germany
  • Investigational Site Number : 2760003
    Rostock, 18057, Germany
  • Investigational Site Number : 7020002
    Singapore, 119074, Singapore
  • Investigational Site Number : 7020003
    Singapore, 169608, Singapore
  • Investigational Site Number : 7020001
    Singapore, Singapore
  • Investigational Site Number : 7240004
    Barcelona, Barcelona [Barcelona] 08035, Spain
  • Investigational Site Number : 7240003
    L'Hospitalet de Llobregat, Barcelona [Barcelona] 08907, Spain
  • Investigational Site Number : 7240002
    Madrid, Madrid, Comunidad de 28046, Spain
  • Investigational Site Number : 7240001
    Barcelona, 08036, Spain
  • Investigational Site Number : 7640001
    Bangkok, 10330, Thailand
  • Investigational Site Number : 7640002
    Bangkok, Thailand
  • Investigational Site Number : 7640003
    Nonthaburi, 11000, Thailand
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in May 2022, 7 months.

Results were first posted in May 2025, 2 years 11 months after primary completion. A results delay was requested in May 2023.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2021
First posted
Aug 18, 2021
StartActual
Oct 7, 2021
Primary completionActual
May 23, 2022
CompletionEst.
Apr 23, 2027
Results delay requested
May 16, 2023
Results first posted
May 21, 2025
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05011123
Responsible party
Sponsor
First posted
Aug 18, 2021
Start date
Oct 7, 2021
Primary completion
May 23, 2022
Completion
Apr 23, 2027 (estimated)
Results posted
May 21, 2025
Last update
Jun 1, 2026

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Yellow Fever Vaccine

Start the discussion